Group
anti-CCR4 mAb
Group Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Mechanism of Action | Anti-CCR4 antibody |
| Drugs in group | Mogamulizumab |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Theoretical immune synergy via Treg depletion; no DNA-level sensitization (Yoshie, Cancers, 2021; Maeda et al., Nature Communications, 2021). Because it removes regulatory T cells and can drive severe cutaneous/immune reactions, a theoretical increase in cutaneous/immune inflammation overlapping in-field skin reactions is conceivable.
The data above refer to patients treated with anti-CCR4 mAb as the sole drug class,
excluding any concurrent use of drugs from other groups.
Individual Drugs
Select a drug to view its individual evidence base (drug + SBRT, no other concurrent systemic drugs). Drugs without available data are shown greyed out.